IBT
SWTX

International Biotechnology Trust’s SpringWorks Therapeutics SWTX Stock Holding History

International Biotechnology Trust’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-401
Closed -$16.3K – 79
2022
Q2 		$16.3K Sell
401
-15,899
-98% -$581K 0.17% 68
2022
Q1 		$1.38M Sell
16,300
-8,700
-35% -$498K 0.31% 49
2021
Q4 		$1.55M Hold
25,000
– – 0.35% 49
2021
Q3 		$1.58M Buy
+25,000
New +$1.93M 0.38% 45

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

International Biotechnology Trust's SWTX Position: Q3 2022 in Review

International Biotechnology Trust sold out of SpringWorks Therapeutics (SWTX) in Q3 2022, closing a stake of 401 shares — an estimated $16.3K sold.

International Biotechnology Trust first reported a position in SWTX in Q3 2021 and held it in 4 quarters. The position peaked at $1.58M in Q3 2021. 148 funds tracked by Wall St. Rank hold SWTX as of Q3 2022.

  • International Biotechnology Trust reported no remaining SpringWorks Therapeutics position as of Q3 2022 after selling out during the quarter.
  • International Biotechnology Trust sold 401 SpringWorks Therapeutics shares in Q3 2022, an estimated $16.3K.
  • International Biotechnology Trust first reported a position in SpringWorks Therapeutics in Q3 2021 and held it in 4 quarters.
  • International Biotechnology Trust's SpringWorks Therapeutics position peaked at $1.58M in Q3 2021.
  • 148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2022.

Based on International Biotechnology Trust's 13F filing for Q3 2022, filed 8 Nov 2022.